IDYA - IDEAYA wins key milestone in GSK deal as FDA clears cancer trial
2023-08-21 08:31:22 ET
More on GSK, IDEAYA, etc.
- Ideaya Biosciences: Eye Cancer Therapy Drives Gains - More Upside Ahead
- GSK: A Muted Valuation And Good Dividend Yield
- GSK Stock: Optimistic After Solid Q2 Growth And Solidifying Guidance
- GSK Rating Upgraded To Buy On New Earning Asset
- GSK's Zantac Settlement: Financial Impact And Investor Outlook
- Ideaya announces FDA nod to run Amgen-sponsored tumor study
For further details see:
IDEAYA wins key milestone in GSK deal as FDA clears cancer trial